N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.
Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to combat diabetic nephropathy has not yet been established. In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease.
Department of Diabetology and Endocrinology, Kanazawa Medical University Uchinada, Ishikawa, Japan.
Keizo
K
Kanasaki
Department of Diabetology and Endocrinology, Kanazawa Medical University Uchinada, Ishikawa, Japan.
Takako
T
Nagai
Department of Diabetology and Endocrinology, Kanazawa Medical University Uchinada, Ishikawa, Japan.
Kyoko
K
Nitta
Department of Diabetology and Endocrinology, Kanazawa Medical University Uchinada, Ishikawa, Japan.
Munehiro
M
Kitada
Department of Diabetology and Endocrinology, Kanazawa Medical University Uchinada, Ishikawa, Japan.
Daisuke
D
Koya
ACE-I; arb; diabetes mellitus; fibroblast; kidney fibrosis